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G13 is a divergent member of the G subunit family
considered to be a component of the gustducin G-pro-
tein heterotrimer involved in bitter and sweet taste re-
ception in taste bud cells. G13 contains a C-terminal
asparagine-proline-tryptophan (NPW) tripeptide, a hall-
mark of RGS protein G-like (GGL) domains which
dimerize exclusively with G5 subunits. In this study,
we investigated the functional range of G13 assembly
with G subunits using multiple assays of G associa-
tion and G effector modulation. G13 was observed to
associate with all five G subunits (G1–5) upon co-trans-
lation in vitro, as well as function with all five G sub-
units in the modulation of Kir3.1/3.4 (GIRK1/4) potas-
sium and N-type (1B) calcium channels. Multiple G/
G13 pairings were also functional in cellular assays of
phospholipase C (PLC) 2 activation and inhibition of
Gq-stimulated PLC1 activity. However, upon cellular
co-expression of G13 with different G subunits, only
G1/G13, G3/G13, and G4/G13 pairings were found to
form stable dimers detectable by co-immunoprecipita-
tion under high-detergent cell lysis conditions. Collec-
tively, these data indicate that G13 forms functional
G dimers with a range of G subunits. Coupled with
our detection of G13 mRNA in mouse and human brain
and retina, these results imply that this divergent G
subunit can act in signal transduction pathways other
than that dedicated to taste reception in sensory lingual
tissue.
One major class of cellular signal transduction pathways is
controlled by heterotrimeric guanine nucleotide-binding pro-
teins (“G proteins”). The conventional model of heterotrimeric
G-protein signaling involves serpentine cell-surface receptors
(G protein-coupled receptors) coupled to a membrane-associ-
ated heterotrimer composed of a GTP-hydrolyzing G subunit
and a G dimeric partner (1, 2). The WD-repeat -propeller
protein G and the -helical isoprenylated polypeptide G form
an obligate heterodimer that binds tightly to GDP-bound G,
enhancing G coupling to receptor and inhibiting its release of
GDP. Guanine nucleotide exchange activity of agonist-occupied
G protein-coupled receptors facilitates dissociation of GGTP
and G subunits and allows both moieties to modulate a
variety of downstream effectors; for the free G dimer, these
effectors include the second messenger generators adenylyl
cyclase and phospholipase C- (PLC)1 as well as ion channels
such as G protein-coupled inward-rectifying potassium (GIRK)
channels and N-type calcium channels (3, 4).
Considerable functional diversity is possible within the large
combinatorial range of potential G dimers (5, 6), given the
existence of at least six G subunits (G1–4, the outlier G5,
and its retinal-specific isoform G5L; Refs. 7 and 8) and 11 G
subunits (three farnesylated and eight geranylgeranylated spe-
cies; Fig. 1). However, outside the unique nature of G1 (the
farnesylated G of the retinal phototransduction cascade; Refs.
9–12), specific roles for particular G subunits in the G- or
effector-binding capacity of G remain elusive. The G
polypeptide is not thought to contribute to the interaction be-
tween G and GGDP, based on analyses of atomic resolution
structures of Gt11 and Gi112 complexes (13–16). The
particular isoprenyl lipid group attached to the G C terminus,
however, may modulate G-, receptor-, and/or effector-coupling
efficiencies of G dimers (11, 12).
A divergent member of the G subunit family, G13, was
recently cloned from mouse neuroepithelial taste receptor cells
(17) and, independently, in a functional screen for mouse brain
mRNAs that exert a growth inhibitory effect after expression in
Escherichia coli (18). G13 is unique in possessing an aspara-
gine-proline-tryptophan (NPW) tripeptide prior to the C-termi-
nal isoprenylation signal sequence; this conserved tripeptide
ends in phenylalanine (i.e. NPF) in all other mammalian G
polypeptides. The NPW motif is also found within the G-like
(GGL) domains of the R7 subfamily of mammalian RGS pro-
teins (RGS6, -7, -9, and -11; Fig. 1B). We and others recently
have shown that GGL domains specify a uniquely selective
association with G5 isoforms (reviewed in Ref. 19). Moreover,
molecular modeling and mutagenesis of GGL domains and G
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subunits (20, 21) led us to identify the NPW motif as a poten-
tially critical component of the absolute selectivity of GGL/G5
interactions; we termed this the “Trp-274 hypothesis” (21). In
this report, we describe the assembly of G13 with G isotypes
and the functional range of these dimers in both G association
and downstream effector activation. In particular, we address
whether the Trp-274 hypothesis of exclusive G5 association
holds true for this divergent G subunit.
EXPERIMENTAL PROCEDURES
Expression Constructs—The entire open reading frame of mouse
G13 was amplified by PCR (sense primer 5-GGGATCCGACGCCAT-
GGAGGAGTGGGATG-3, antisense primer 5-GTCTAGAGTGTGGGT-
CAGGCTCATAGG-3) from a MarathonTM mouse brain cDNA library
(CLONTECH), digested with EcoRI and XbaI, and subcloned in-frame
with an N-terminal tandem hemagglutinin (HA)-epitope tag into
pcDNA3.1 (Invitrogen) as previously described (20). G protein -sub-
unit constructs with an N-terminal Myc-epitope tag, as well as wild-
type and F61W mutant G2 expression constructs have previously been
described (21, 22).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and
Northern Blot Analyses—MarathonTM cDNA pools from human heart,
brain, spleen, retina, and lymph node poly(A) mRNA (CLONTECH)
were amplified by PCR using primer sets specific for human G13 (sense
primer 5-TTGTCATTGTCCCTCCGCTGTCAC-3, antisense primer 5-
GCTCACAGGATGGTGCATTTG-3) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; sense primer 5-GACCACAGTCCATGCCAT-
CACT-3, antisense primer 5-TCCACCACCCTGTTGCTGTAG-3)
mRNAs. The 273-bp human brain G13 PCR product, encoding the
entire open reading frame, was cloned into the vector pCR2.1 using the
TOPO-TA cloning kit (Invitrogen). An EcoRI fragment of this construct
was labeled with [-32P]dATP (Amersham Bioscience Inc.) by random
priming (StripEZ, Ambion), and hybridized under stringent conditions
with a human brain multiple tissue Northern (MTNTM) blot (CLON-
TECH) using the NorthernMax system (Ambion). A mouse tissue
MTNTM blot was similarly hybridized with a 32P-labeled 301-bp EcoRI/
XbaI fragment of mouse G13 cDNA. To control for RNA loading and
quality, both MTNTM blots were also hybridized with a commercially
available GAPDH cDNA probe (Ambion).
In Vitro G/G Co-translation and Immunoprecipitation—In vitro
transcription and translation reactions were performed using the
TNTTM reticulocyte lysate system (Promega). T7 promoter-based met-
abolic 35S labeling of HA-tagged G13 or G2(F61W) co-expressed with
one of five Myc-tagged G subunit expression vectors (G1–5) was per-
formed as previously described (20, 21, 23). Briefly, G proteins were
immunoprecipitated (IP) using anti-HA monoclonal antibody 12CA5
(Roche Molecular Biochemicals) and protein A-Sepharose (Sigma) in
Buffer D (50 mM NaCl, 10 mM MgCl2, 50 mM Tris, pH 8.0, 1 mM EDTA,
10 mM -mercaptoethanol, 20% glycerol, 0.05% C12E10). Immunopre-
cipitated complexes were washed three times with 0.4 ml of Buffer D.
Co-precipitating [35S]methionine-labeled G and G subunits were
identified by SDS-PAGE on Novex 14% Tris-glycine gels (Invitrogen)
followed by direct autoradiography.
Cellular G/G Co-immunoprecipitation—Detailed experimental
procedures were provided previously (20, 21, 23) and only differences
from published protocols are provided below. Transient co-transfections
of HEK293T cell monolayers with Myc-tagged G and HA-tagged G
expression constructs were performed using Effectene transfection re-
agent (Qiagen) according to the manufacturer’s instructions. Trans-
fected cells were harvested 48 h post-transfection by scraping into 1 ml
of RIPA-150 buffer (150 mM NaCl, 50 mM Hepes, pH 7.5, 20 mM EDTA,
0.5% deoxycholate, 1% Nonidet P-40, 0.1% SDS, CompleteTM Mini
EDTA-free protease inhibitor mixture (Roche Molecular Biochemicals)).
Lysates were prepared by passing cell suspension 10 times through a
23-gauge needle followed by centrifuging at 16,000  g for 5 min at 4 °C
to remove insoluble material. Supernatants were adjusted to 1 mg/ml
total protein (concentrations measured using Bio-Rad DC protein assay
reagent) and precleared for 45 min with 20 l of 50% (v/v) protein
A/G-agarose beads (Santa Cruz). Following removal of beads by centrif-
ugation at 10,000  g for 1 min, the supernatants were transferred to
fresh tubes containing anti-HA monoclonal antibody 12CA5 (Roche
Molecular Biochemicals) and incubated with constant rotation for 1 h at
4 °C. The immune complexes were centrifuged, and the supernatants
were transferred to fresh tubes containing 40 l of 50% (v/v) protein A/G
beads. The complexes were rotated at 4 °C for 1 h, and then centrifuged
at 10,000  g for 1 min to collect the beads. The protein A/G beads were
washed twice in RIPA-500 buffer (21), followed by three washes in
RIPA-150 buffer. Immunocomplexes were eluted from the beads by
adding 50 l of Laemmli sample buffer and boiling for 5 min. Proteins
were separated on 12% SDS-PAGE gels and electroblotted onto polyvi-
nylidene difluoride membranes (Millipore) for detection of G subunits
with anti-Myc mouse monoclonal antibody conjugated to horseradish
peroxidase (9E10-HRP; Roche Molecular Biochemicals), followed by
enhanced chemiluminescence (Amersham Bioscience, Inc.). G sub-
units were detected using anti-HA rat monoclonal antibody 3F10-horse-
radish peroxidase (Roche Molecular Biochemicals).
GIRK Channel Electrophysiology—Transient transfection and elec-
trophysiological recordings of the stable G1,4 cell line, a HEK293 de-
rivative line expressing GIRK1 and GIRK4 potassium channel sub-
units, were performed as recently described (24). Briefly, G and G
expression plasmids were co-transfected at a concentration of 6 g each
per 35-mm culture dish, along with 1 g per dish pGreenLantern
(Invitrogen), a plasmid encoding enhanced green fluorescent protein
(GFP). Electrophysiological recordings were acquired and analyzed us-
ing an Axopatch 200A patch clamp amplifier and the pCLAMP program
suite (Axon Instruments). Inwardly rectifying whole cell currents were
evoked from cells held at 50 mV while applying a voltage ramp
command at 0.1 Hz ( 90 mV; 0.1 V/s). Slope conductance was ob-
tained from a linear fit to current voltage data over the range of 100
to 120 mV. Statistical analysis was performed using ANOVA, with
post-hoc Bonferroni test. All GIRK channel data are presented as
mean  S.E., with p  0.05 considered statistically significant.
N-type Ca2 Channel Electrophysiology—Voltage-dependent inhibi-
tion of calcium channels by G subunit expression was studied in
C2D7 cells, a HEK293-derivative line expressing human 1B (N-type)
Ca2 channels (1B, 2, and 1–3 subunits) (25). Cells were transiently
transfected with 5 g of G and 5 g of G DNA, along with 1 g of
commercially available GFP vector (Invitrogen), as previously described
(26). Cell culture, cell identification, and whole cell patch clamp of Ba2
current (n  6	11) were performed as previously described (26). Pre-
pulse facilitation ratios, indicative of G-mediated, voltage-dependent
inhibition, were calculated from these currents and analyzed as de-
scribed by Simen and Miller (25). Multiple comparisons of calcium
current results were performed using one-way ANOVA, followed by a
nonparametric Kolmogorov-Smirnov test.
PLC2 Activation by G Subunits—COS-7 cells were maintained at
5% CO2 in Dulbecco’s modified Eagle’s medium with high glucose and
supplemented with 10% fetal calf serum and antibiotics. Approximately
24 h prior to transfection, cells were replated into 12-well plates at a
density of 7.5  105 cells per well. Subconfluent cells were transfected
using Fugene transfection reagent (Roche Molecular Biochemicals)
with 300 ng of PLC2 vector, 200 ng each of appropriate G and/or G
subunit expression vectors, and sufficient pcDNA3.1 vector to achieve
700 ng/well total DNA. After incubating 24 h with DNA and transfec-
tion reagent, the medium was removed and replaced with 400 l of
inositol-free and serum-free Dulbecco’s modified Eagle’s medium con-
taining 1 Ci of myo-[3H]inositol (American Radiolabeled Chemicals,
Inc.). To initiate the accumulation of radiolabeled inositol phosphates,
LiCl (10 mM final concentration) was added to the labeling medium and
cells were incubated for 1 h at 37 °C. Medium was then aspirated and
cells were lysed by adding ice-cold 50 mM formic acid and incubated on
ice for 20 min. After neutralization with 250 l of 150 mM NH4OH,
lysates were loaded onto Dowex ion exchange columns, and washed
with 10 ml of water and 10 ml of 50 mM formic acid. Inositol phosphates
were eluted with 5 ml of 1.2 M ammonium formate, 100 mM formic acid.
G Subunit Inhibition of Gq-stimulated PLC1 Activity—G sub-
unit-mediated inhibition of Gq-stimulated [3H]inositol phosphate ac-
cumulation was measured as described above, except that COS-7 cells
were transiently transfected with 20 ng of Gq vector in addition to 300
ng of PLC1 vector, 200 ng each of the indicated G and/or G subunit
expression vectors, and pcDNA3.1 vector DNA to a total of 720 ng/well.
RESULTS
In Silico Identification of Novel G Sequences—In a continu-
ing search for G-like (GGL) polypeptide sequences (20), we
employed the Simple Modular Architecture Research Tool
(SMART; Ref. 27) to identify uncharacterized GGL sequences
among anonymous open reading frames derived from eukary-
otic genome sequencing projects. We recently reported the
identification of two open reading frames from genes of the
Drosophila melanogaster genome (CG15844 and CG18511)
that possess GGL domains (19). The latter predicted polypep-
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tide data base record (CG18511, also known in the Celera data
base as CP42246; Ref. 28) is, in fact, an erroneous C-terminal
sequence extension of a known G subunit, the Drosophila
visual G subunit Ge (29). More recently, we identified a GGL
domain within a predicted 89-amino acid polypeptide computed
from genomic DNA sequence of a 2-Mb span of human chromo-
some 16p13.3 (GenBankTM accession number AL031033; pro-
tein product C321D2.5); this predicted open reading frame data
base record is also an erroneous sequence extension of a re-
cently isolated human G subunit, G13 (17).
Alignment of the correct polypeptide sequences of human
G13 and Drosophila Ge, along with corresponding orthologs
from mouse (mG13; Ref. 18) and C. elegans (cG2; Ref. 29),
revealed 100% conservation of a unique asparagine-proline-
tryptophan (NPW) tripeptide sequence at the C terminus prior
to the CAAX box (Fig. 1A). While the presence of an NPW motif
was found to be unique among conventional, isoprenylated G
subunits (e.g. comparing hG13 to all other human G sub-
units; Fig. 1B), this NPW motif is a hallmark of the internal
GGL domains of R7 subfamily (or “C-subfamily”) RGS proteins
(20, 21). Pairwise comparisons of all human G and GGL do-
main sequences (Fig. 1C) confirmed the divergent nature of the
NPW motif-containing G subunit.
Expression of G13 in Neural Tissue—The human and mouse
G13 open reading frames were cloned using RT-PCR. cDNA
pools from human and mouse whole brain and retinal tissues
gave detectable RT-PCR products, whereas neither G13 prod-
uct was detected in lymph node, spleen, or heart cDNA samples
(Fig. 2A and data not shown). The RT-PCR products from brain
cDNA were cloned, sequence verified, and used as probes in
Northern blot analyses of G13 expression. Analysis of a mouse
multiple tissue Northern blot revealed the expression of a
	0.5-kb murine G13 transcript that was restricted to brain
(Fig. 2B). The human G13 mRNA was observed in whole brain
as a single 	1.3-kb transcript (Fig. 2C) and, among several
brain regions tested, was specifically expressed in the thala-
mus. These results are comparable to the brain-specific expres-
sion observed in complementary human multiple tissue and
mouse brain subregion Northern blots by Huang and col-
leagues (17). In addition, serial analysis of gene expression
maps and EST profiles of the human and mouse G13 se-
quences (UniGene clusters Hs.247888 and Mm.45263; Ref. 30)
also indicate a primarily brain-specific expression pattern. In
total, these findings suggest that G13 expression is limited
primarily to sensory epithelia and neural tissues.
In Vitro and Cellular Assembly of G/G13 Dimers—We
previously hypothesized that the NPW motif of GGL domains
plays a critical role in the exclusive G5 association by R7
subfamily RGS proteins (21). We therefore tested the NPW
motif-containing G13 subunit for its G association specificity.
FIG. 1. Sequence comparisons between G13, other G subunits, and GGL domains. A, amino acid alignment of NPW-containing G
subunits from Homo sapiens (h), Mus musculus (m), Drosophila melanogaster (d), and Caenorhabditis elegans (c) (GenBankTM accession numbers
7706567, 11967949, 6782318, and 7498606, respectively). Identical amino acids are indicated by a period (.) and gaps with a dash (). The end of
the unprocessed polypeptide chain is denoted with an asterisk (*). NPW motif is overlined. B, multiple sequence alignment of human G subunits
and GGL domains of human RGS proteins. Black boxes depict identical amino acids shared by at least 60% of sequences within alignment; NPW
motif shared between GGL domains and G13 is overlined and underlined, respectively. C, pairwise sequence similarity relationships between
human G subunits and GGL domains as computed by the Wisconsin GCG Pileup program using default parameters. The hG13 subunit is
predicted to be geranylgeranylated based on the C-terminal leucine of the CAAX box sequence (45, 46). GenBankTM accession numbers for human
sequences used: RGS7, 11140809; RGS6, 4972617; RGS11, 4506507; RGS9, 4506521; G11, 4758448; G1, 11386179; G8, 3023844; G7, 4826746;
G12, 10047118; G4, 4758450; G2, 11277005; G3, 6912394; G5, 4885287; G10, 4758446; G13, 7706567.
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T7 promoter-based expression vectors for HA epitope-tagged
G13 (or G2(F61W) as a positive control; Ref. 21), along with
one of five Myc-tagged G subunit expression vectors (G1–5),
were co-transcribed and translated in reticulocyte lysates as
previously described (20, 21, 23). G proteins were immunopre-
cipitated using anti-HA monoclonal antibody and the immuno-
complexes were washed with low detergent conditions (0.05%
C12E10) prior to detection of associated, [
35S]methionine-
labeled G subunits by SDS-PAGE and autoradiography. As
previously reported (21), substituting tryptophan for phenyl-
alanine in the NPF motif of G2 (i.e. the “F61W” point muta-
tion) facilitates G2 dimerization with all five G subunits
(including G5) in low-detergent conditions (Fig. 3A, left panel).
Similarly, co-translated G13 bound to all five G subunits in
these low-detergent conditions (Fig. 3A, right panel).
To test G/G13 dimer assembly in a cellular context, expres-
sion vectors for HA-tagged G13, G2, or RGS11 proteins were
transiently transfected into HEK293T cells, along with one of
five Myc-tagged G subunit expression vectors (G1–5). Lysates
of transfected cells were immunoprecipitated with anti-HA an-
tibody and immunoblotted with anti-Myc antibody to detect
bound G subunits. As shown in Fig. 3B (right panel), only
G1/G13, G3/G13, and G4/G13 dimers were detected in
cellular lysates by co-immunoprecipitation. The apparent lack
of detectable G13 association with G2 and G5 in this exper-
iment was not the result of deficient G subunit expression
levels (i.e. Fig. 3B, Lysate Blot:anti-Myc), nor the result of a
functional deficiency in expressed G2 and G5 proteins, since
the positive controls G2 and RGS11 bound avidly to G2 and
G5 subunits, respectively (Fig. 3B, left panel). These findings
suggest that under the high-detergent conditions used for this
cellular co-immunoprecipitation assay (i.e. RIPA buffer with
0.5% deoxycholate, 1% Nonidet P-40, and 0.1% SDS), G13
remains stably associated with G1, G3, and G4, and is not,
or is very weakly, associated with G2 and G5.
Modulation of K Channels by G/G13 Pairs—The capacity
of G13, in combination with each of the G subunits, to mod-
ulate GIRK currents was examined using whole cell patch
clamp electrophysiology. G1,4 cells, stably expressing Kir3.1/
3.4 (GIRK1/4) channels (24), were transiently transfected with
GFP and empty vector (control) or GFP and G/G vector pairs.
GIRK channel conductance in cells co-transfected with G13
and one of the first four G subunits (G1–4) was markedly
enhanced (Fig. 4). The current activation elicited by G
dimers consisting of G1–4 in combination with G13 was not
significantly different from that observed with cognate G
dimers formed with G2 (e.g. 113 versus 12; Fig. 4A). In
contrast, G1,4 cells co-transfected with G13 and G5 subunits
displayed significantly diminished GIRK currents relative to
vector-transfected cells (Fig. 4B, and inset of C); this observa-
tion is consistent with our previous report that G5 containing
dimers 52 and 511 inhibit, rather than activate, GIRK1,4
and GIRK1,2 channels (24). Collectively, these findings suggest
that G13 associates nonselectively with all G subunits to
modulate GIRK channel currents.
Inhibition of N-type Calcium Channels by G/G13 Pairs—
The HEK293-derived cell line C2D7 stably expresses human
1B (N-type) Ca
2 channels and serves as a useful model for the
FIG. 2. Expression profile of G13 mRNA in human and mouse tissue samples. A, cDNA pools from the indicated human poly(A)
 RNA
sources were PCR amplified using primer sets specific for human G13 and GAPDH mRNAs. Predicted molecular weights of G13 and GAPDH
amplicons are 273 and 453 bp, respectively. “Mr” denotes DNA molecular weight standards. B, mouse multiple tissue Northern blot (2 g of
poly(A) RNA per lane) was probed in sequential fashion with randomly primed 32P-labeled mouse G13 and GAPDH cDNA probes. “Sk muscle”
denotes skeletal muscle mRNA lane. C, Northern blot of various human brain anatomical features (2 g of poly(A) RNA per lane) was probed in
sequential fashion with randomly primed 32P-labeled human G13 and GAPDH cDNA probes.
FIG. 3. G binding specificity of G13 as measured by in vitro
and cellular co-immunoprecipitations. A, G subunits were co-
translated in vitro in reticulocyte lysates with HA-epitope tagged
G2(F61W) (left panel) or G13 subunits (right panel). HA-tagged G
subunits were immunoprecipitated (IP) with anti-HA monoclonal anti-
body, washed under low detergent conditions (0.05% C12E10), and bound
G subunits were visualized by autoradiography after SDS-PAGE.
Clarified supernatants were also visualized in the same manner to
confirm uniform G subunit expression. Results displayed are repre-
sentative of three independent experiments. B, HEK293T cells were
transiently co-transfected with expression vectors for HA-tagged G13
(right panel), or G2 or RGS11 as positive controls (left panel), along
with one of five Myc-tagged G subunit expression vectors (1–5). Cell
lysates were immunoprecipitated (IP) with anti-HA mAb, and coimmu-
noprecipitating G subunits were detected by immunoblotting (Blot)
with anti-Myc monoclonal antibody. To discount lack of G or G
expression as a trivial explanation for lack of observable G2 and G5
coimmunoprecipitation with G13, cell lysates were directly immuno-
blotted for G expression using anti-Myc monoclonal antibody (“Ly-
sate”), and G species were directly detected by anti-HA mAb immu-
noblotting (lower panels).
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study of G-protein subunit effects on Ca2 channel activity (25,
26). To determine whether G13 forms G dimers capable of
modulating Ca2 channel activity, C2D7 cells were transiently
transfected with GFP and empty vector (control) or with GFP
and combinations of individual G subunits (G1–5) and HA-
tagged G2 or G13. Total Ba
2 currents (IBa) were recorded
from fluorescent cells in the whole cell configuration as previ-
ously described (26). As shown in Fig. 5 (inset), a test pulse to
10 mV (test pulse 1) elicited a biphasic IBa in vector-trans-
fected control C2D7 cells consisting of a rapid activation phase,
followed by a slower inactivation phase. A 50-ms prepulse to
80 mV preceding the test pulse (test pulse 2) did not affect the
characteristics of this current. In cells co-transfected with G1
and G2, IBa inhibition during a single depolarizing test pulse
is apparent in the current tracing by the reduced current am-
plitude and kinetic slowing of activation (Fig. 5, inset, tracing
1). The depolarizing prepulse relieves this inhibition by G12,
and the resulting facilitation is seen in the increased IBa during
test pulse 2 (Fig. 5, inset, tracing 2), compared with test pulse
1. The “facilitation ratio,” defined as the ratio of the current
amplitude during the peak of test pulse 2 divided by the cur-
rent during test pulse 1 at the same time point, reflects the
magnitude of G-mediated inhibition of voltage-dependent
N-type Ca2 channel currents (26).
Table I and Fig. 5 illustrate the effect of expressing isolated
G or G subunits, or combinations of G and G subunits, in
C2D7 cells on Ca2 channel facilitation ratios. In cells trans-
fected with GFP and a single G or G subunit, near identical
IBa tracings were obtained during test pulses with and without
the depolarizing prepulse, indicating that individual subunits
fail to produce voltage-dependent inhibition of N-type Ca2
channels in these cells. In contrast, all tested G/G2 and
G/G13 pairs inhibited these currents, as demonstrated by the
significantly enhanced facilitation ratios compared with control
(Fig. 5). Notably, however, G13 was less efficacious than G2
when paired with G2 and G5 in this effector paradigm; in
particular, the G5/G13 pairing yielded a facilitation ratio that
was not statistically different from that resulting by G13
transfection alone (Fig. 5).
Activation of PLC2 by G/G13 Pairs—Phosphatidylino-
sitol-specific PLC isoforms are activated by Gq/11 and G
subunits of heterotrimeric G-proteins (31–35); in particular,
PLC1 is more responsive to Gq activation than PLC2,
whereas the opposite is true for G-mediated activation
(36). We therefore examined the ability of G13 to participate
in the formation of PLC2 activating G dimers in trans-
fected COS-7 cells. Transfection of G1 with G2 or G13
promoted 	2-fold increases in [3H]inositol phosphate forma-
FIG. 4. GIRK1/4 channel currents are modulated equivalently by G/G2 and G/G13 dimers. A and B represent sample current traces
from control cells (i.e. G1,4 cells transfected with GFP alone) and from G1,4 cells transiently transfected with the indicated G and/or G subunits.
C, bar graph of averaged data ( S.E.) depicts the GIRK conductance in cells transfected with GFP and empty vector (control) or GFP and the
indicated G pairs. As a measure of channel activity, peak whole cell conductance (nS) was determined by patch clamp recordings as the slope
of a ramp I-V curve between 100 and 120 mV. Numerals in parentheses denote number of cells tested for each transfection paradigm. Asterisks
denote statistically significant differences from control (p  0.05 by ANOVA, with post-hoc Bonferroni test). As previously reported (Ref. 24), G
or G subunits expressed alone have no significant effect on GIRK conductance: e.g. G2 alone  10.5  1.0 nS (14 cells), G2 alone  8.4  1.0
nS (15 cells), and G13 alone  12.7  2.0 nS (16 cells) versus empty vector  9.9  0.8 nS (33 cells). Inset, averaged data ( S.E.) from control
and G5-expressing cells are shown on an expanded scale. As previously reported (24), G5-containing dimers inhibit G-stimulated GIRK
channels.
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tion (Fig. 6), presumably mediated by the endogenous, G-
responsive phospholipases constitutively present in COS-7
cells. The additional transfection of PLC2 expression vector
with either G1/G2 or G1/G13 pairs resulted in similar
6–7-fold enhancements of inositol phosphate formation over
that of the G pairs alone. Likewise, G13 was equally
effective as G2 in activating PLC2 when combined with
G3 and G4. (It should be noted that expression of G3-
containing dimers repeatedly demonstrated only weak acti-
vation of PLC2; the pcDNA3.1-based human G3 expression
vector was sequenced independently in two different labora-
tories and confirmed to contain the G3 wild-type sequence,
discounting the possibility of mutation rendering this G
subunit inactive.) In contrast to the similar activation of
PLC2 observed upon combining either G2 or G13 with
G1, -3, and -4, the G2/G13 and G5/G13 pairings did not
activate PLC2 to the same degree as the analogous pairings
with G2 (Fig. 6).
Inhibition of Gq-stimulated PLC1 Activity by G/G13
Pairs—Since PLC1 is relatively insensitive to activation by
G, expression of free G dimers inhibits Gq-mediated
PLC1 activation, presumably by binding to, and thus seques-
tering, Gq in its GDP-bound form (37, 38). Thus, the ability of
G13 to bind G subunits and participate in Gq coupling and
sequestration was examined using inhibition of Gq-stimu-
lated PLC1 activity as an effector end point. COS-7 cells were
transfected with Gq, PLC1, and indicated G and/or G
subunit expression vectors and [3H]inositol phosphate accumu-
lation was measured as described above. When paired with
G1–4, expression of either G2 or G13 inhibited PLC1 activ-
ity (Fig. 7), presumably by sequestration of Gq via heterotri-
mer formation. In contrast, neither G5/G2 nor G5/G13 in-
FIG. 5. Inhibition of N-type Ca2 channels by G/G2 and G/G13 dimers. HEK293 cells stably expressing human 1B (N-type) Ca
2
channels (1B, 2, and 1–3 subunits; “C2D7” cells) were transiently transfected with G/G2 or G/G13 expression vector pairs to study their
effects on Ca2 channel activity measured by whole cell patch clamp electrophysiological recordings. Inset, in untransfected C2D7 cells, a 50-ms
depolarizing test pulse to 10 mV (“test pulse 1”) from a 80 mV holding potential elicited a rapidly activating and slowing inactivating Ba2
current (IBa) which was not significantly altered by a 50-ms prepulse to 80 mV (“test pulse 2”) (26). Expression of functional G subunits reduced
the IBa amplitude upon test pulse 1 and slows its activation rate; this inhibition was “relieved” by the depolarizing prepulse of test pulse 2. The
facilitation ratio, an index of voltage-dependent inhibition of Ca2 channels by G subunits, is defined as the peak current of test pulse 2 divided
by the current of test pulse 1 at the same time point. Bar graph depicts facilitation ratios (mean  S.E.) derived from cells transfected either with
single subunit expression vectors (as negative controls) or with indicated G/G pairs (see Table I). Numerals in parentheses denote number of cells
tested for each transfection paradigm. Asterisks (*) denote statistically significant differences from control cells and number signs (#) denote
statistically significant decreases in facilitation ratio for a particular G/G13 pairing over that observed for matching G/G2 pairing (p  0.05,
one-way ANOVA followed by nonparametric Kolmogorov-Smirnov test (n  6–11)).
TABLE I
Inhibition of N-type Ca2 channels by G/G2 and G/G13 dimers




pulse 2 Facilitation ratio
pA
(mean  S.E.) (mean  S.E.) (mean  S.E.)
Control 8 1983  377 1951  340 0.99  0.01
1 8 2417  386 2579  410 1.10  0.06
2 10 2092  401 2142  403 1.04  0.02
3 10 2540  593 2768  597 1.17  0.05
4 11 2278  458 2400  468 1.09  0.04
5 11 1791  748 1796  771 1.01  0.02
2 8 1366  309 1394  306 1.11  0.09
13 11 1331  320 1470  321 1.15  0.03
12 6 904  294 1473  441 1.82  0.22
113 6 638  212 907  268 1.55  0.09
22 9 348  67 1022  243 2.84  0.28
213 6 725  177 1244  307 1.80  0.10
32 8 425  106 791  183 2.01  0.16
313 8 363  119 646  237 1.70  0.09
42 10 793  356 1512  416 2.90  0.48
413 8 1214  389 2134  594 2.10  0.31
52 6 785  191 1606  432 2.04  0.10
513 8 693  140 926  146 1.45  0.11
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hibited Gq-stimulated PLC1 activity (Fig. 7). Similarly,
G5L/G2 and G5L/G13 pairings also failed to inhibit Gq-
stimulated PLC1 activity (data not shown).
DISCUSSION
All of the functional assays of G/G13 dimer activity pre-
sented here indicate that the divergent, NPW motif-containing
G13 polypeptide is capable of interacting with all five G
subunits to varying degrees (summarized in Table II). More-
over, all five G/G13 combinations are capable of forming
dimers upon coincident translation in vitro. Thus, our initial
speculation that G13 might selectively associate with G5, the
outlier G isotype that also exhibits a largely neural expression
pattern (7, 8), is not supported by our results.
In contrast to our results on in vitro dimer assembly and
cellular dimer activity, we were unable to detect stable G2/
G13 or G5/G13 dimers in the lysates of cells co-transfected
with expression vectors for these G and G subunits. We
believe the inability to detect G2/G13 or G5/G13 dimers by
cellular co-immunoprecipitation results from enhanced deter-
gent sensitivity that leads to dimer disruption under high-
detergent cell lysis and immunoprecipitation conditions. This
hypothesis stems from our previous work (21, 23), and that of
Garrison and co-workers (39, 40), detailing the uniquely sensi-
tive nature of the G5/G2 dimer to low levels of detergent that
do not disrupt other conventional G dimers or G5-GGL
complexes (e.g. G5/G2 dimer disruption by sodium cholate in
excess of 	0.25%; Ref. 40). Such a qualitative difference in
dimer stability is not only manifest in the apparent detergent
sensitivity of G2/G13 and G5/G13 dimers, but also in the
reduced efficacy of Ca2 channel inhibition and PLC2 activa-
tion seen upon G2/G13 or G5/G13 co-expression versus cog-
nate G/G2 pairings. The structural basis for this qualitative
difference remains undefined.
The selective modulation of effector functions exhibited by
G5/G13 is, with a single exception, consistent with previous
studies employing G5/G2 dimers (reviewed in Ref. 19). The
G5/G2 dimer has been shown to activate PLC2 (7, 8) and
inhibit both Kir3 channels (24) and N-type Ca2 channels (26,
FIG. 6. Activation of phospholipase
PLC2 by G/G2 and G/G13
dimers. COS-7 cells were transiently
transfected with PLC2 and indicated G
and/or G subunit expression vectors, and
inositol phosphate accumulation was
measured in cells radiolabeled with myo-
[3H]inositol as described under “Experi-
mental Procedures.” Results displayed
are representative of three independent
experiments; all transfections were per-
formed in triplicate.
FIG. 7. Inhibition of Gq-stimulated
PLC1 activity by G/G2 and G/G13
dimers. COS-7 cells were transiently
transfected with Gq, PLC1, and indi-
cated G and/or G subunit expression
vectors. [3H]Inositol phosphate accumula-
tion was measured as described in the
legend to Fig. 6.
TABLE II




G1 G2 G3 G4 G5
In vitro co-immunoprecipitation     
Cellular co-immunoprecipitation     
Inhibition of N-type Ca2 channels  a   /a,b
Activation of PLC2  a /  a
Modulation of Kir3.1/3.4 channelsc 1 1 1 1 2
Inhibition of Gq-stimulated PLC1     
a G/G13 dimer is significantly less active than cognate G/G2
dimer.
b G5/G13 dimer activity is not significantly different than G13
alone.
c Up arrow (1) denotes increased K conductance; down arrow (2)
denotes decreased conductance.
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41), consistent with our findings here using G5/G13. The
observed lack of statistically significant inhibition of N-type
Ca2 channels by G5/G13 over G13 transfection alone may
reflect a need for higher amounts of G5 and G13 expression to
attain robust channel inhibition versus other G/G pairs, a
phenomenon first shown by Ruiz-Velasco and Ikeda (41) for the
G5/G2 dimer.
The single exception is our finding that G5/G2 and G5/
G13 dimers are unable to inhibit Gq-mediated activation of
PLC1 in transfected cells. This is in contrast to the findings of
Garrison and colleagues (39) that G5/G2 interacts with Gq
in measurements of in vitro heterotrimer formation and in vitro
coupling to M1 muscarinic and ETB endothelin receptors (42).
While recombinant G5/G2 dimers may interact with Gq in
vitro, this interaction may be too weak in affinity within a
cellular context to affect PLC1 activation. Moreover, as we
have previously postulated (19), the existence of GGL domains
as avid, native binding partners for G5 implies that hetero-
dimers between G5 and conventional G subunits could
merely represent unnatural and weakly associated dimers that
only inadvertently affect some conventional G effector
systems.
Clearly, our results demonstrate that the functional range of
G13 assembly with G subunits is wider than our original
conjecture of strict G5 specificity. Thus, the presence of an
NPW motif is not predictive of exclusive association solely with
G5 isoforms, a selectivity previously seen with the NPW motif-
containing GGL domains of RGS proteins (19). We are pursu-
ing experimentally derived atomic resolution structural data
on the G5/GGL interface with the goal of identifying the
residue(s) within the G-like polypeptide responsible for exclu-
sive G5 association and thus refining our Trp-274 hypothesis
(21).
Our formal demonstrations of stable G3/G13 dimer forma-
tion using both in vitro and cellular co-immunoprecipitations
confirm one of the speculations of Huang and colleagues (17)
who, in their original report on the cloning of G13, demon-
strated fully coincident expression of G3 and G13 mRNAs in
murine taste receptor cells but were unable to demonstrate
G3/G13 dimer assembly for technical reasons. However, our
results indicate that G3/G13 activates PLC2 weakly if at all,
which is consistent with a previous report (43) using other
G3/G combinations but runs counter to the speculation by
Huang and colleagues (17) that G3/G13 is responsible for
PLC2 activation in bitter taste signal transduction. As one
explanation for this discrepancy, the bitter taste response has
been suggested to rely on a “unique” PLC2 isoform which is
specifically expressed in taste receptor cells (44) yet remains
functionally uncharacterized.
G13 was originally cloned from taste receptor cells and
co-localized with G-gustducin, G1, and G3 transcripts
within mouse circumvallate papillae (17); these results led
Huang and colleagues (17) to suggest that G13, as part of a
gustducin heterotrimer, participates in bitter and sweet taste
signal transduction via G1/G13- or G3/G13-mediated PLC
activation. Our results demonstrating G13 expression in the
central nervous system, as well as association of G13 with all
five G subunits, imply that the functional roles for G13 ex-
tend beyond taste reception. The next challenge will be to
define precisely these other locales and other roles for G13 and
determine whether the divergent nature of its polypeptide se-
quence affects its function in receptor coupling and down-
stream signaling compared with more conventional G
subunits.
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